GBA1 and Parkinson disease: Furthermore, the hypothesis of ceramide accumulation as a pathogenic mechanism in PD patients harboring GBA1 mutations has paved the way for implementing neuroprotective strategies based on using inhibitors of glucosylceramide synthase [18,57].